Nutriband announces FDA granted Type C Meeting for AVERSA FENTANYL

Nutriband (NTRB) announced that the United States Food and Drug Administration, FDA, has granted a Type C Meeting for its lead product, AVERSA FENTANYL. The purpose of the meeting is to specifically provide feedback on the Chemistry, Manufacturing, and Controls, CMC, plans for the product from submission of an Investigational New Drug Application, IND, through approval of a 505(b)(2) New Drug Application, NDA, and subsequent commercialization. The meeting is scheduled as a virtual face-to-face meeting to be held on September 18, 2025 with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine, DAAP, in the Office of Neuroscience, ON, Center for Drug Evaluation and Research, CDER.